EAU 2014 - Poster: Safety and efficacy of ODM-201 in chemotherapy and CYP17-inhibitor naïve patients: Analysis of data from the ARADES and the ARAFOR trials

STOCKHOLM, SWEDEN (UroToday.com) - Presented by T. Tammela,1 C. Massard,2 P. Bono,3 P. Langmuir,4 J. Aspegren,5 A. Vuorela,5 M.V.J. Mustonen,5 and K. Fizazi2 at the 29th Annual European Association of Urology (EAU) Congress - April 11 - 15, 2014 - Stockholmsmässan - Stockholm, Sweden.

EAU-2014-ODM-201-poster thumb

1Tampere University Hospital, Dept. of Urology, Tampere, Finland, 2Institute Gustave Roussy, University of Paris Sud, Dept. of Cancer Medicine, Villejuif, France, 3Helsinki University Hospital, Dept. of Oncology, Helsinki, Finland, 4Endo Pharmaceuticals, Dept. of Clinical Development, Malvern, United States, 5Orion Corporation Orion Pharma, Dept. of Research and Development, Espoo, Finland

 

Conference Coverage
 
Recent data from conferences worldwide
  • 2020 Virtual Congress / September 19-21
  • 2020 BCAN Think Tank Virtual / August 7
  • 2020 Virtual Education Program / August 8-10
  • 2020 Annual Meeting / July 17-19 / EAU Virtual Program
  • SUO - AUA 2020 Summer Webcast / July 18
  • 2020 Annual Meeting / June 27-28 / AUA Live Virtual Program
  • 2020 Annual Meeting / May 29-31 / Virtual Scientific Program
  • 2020 Annual Meeting / February 13-15 / San Francisco, CA
  • 2019 Annual Meeting / December 4-6 / Washington, DC
  • 2019 Annual Meeting / October 3 - October 5 / Aarhus, Denmark
  • 2019 Annual Congress / September 27 - October 1 / Barcelona, Spain
  • 2019 Biennial Meeting / August 29-31 / Basel, Switzerland